Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yeamin Huh

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2025
Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose SelectionYeamin Huh, Ruolun Qiu, John Prybylski, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
The AAPS Journal|January 24, 2024
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic ModelAnas Saadeddin, Vivek Purohit, Yeamin Huh, et al.
The AAPS Journal|February 21, 2024
Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic ModelAnas Saadeddin, Vivek Purohit, Yeamin Huh, et al.
British Journal of Clinical Pharmacology|May 7, 2025
Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450Vivek S Purohit, Yeamin Huh, Martin E Dowty, et al.
The AAPS Journal|March 28, 2023
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsVivek Purohit, Yeamin Huh, Jessica Wojciechowski, et al.
Pediatric Dermatology|February 10, 2025
A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia AreataMercedes E Gonzalez, John Browning, Stacy Smith, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 13, 2010
Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochlorideYeamin Huh, Hyun-Jong Cho, In-Soo Yoon, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 30, 2024
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Sakambari Tripathy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2025
Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose SelectionYeamin Huh, Ruolun Qiu, John Prybylski, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
The AAPS Journal|January 24, 2024
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic ModelAnas Saadeddin, Vivek Purohit, Yeamin Huh, et al.
The AAPS Journal|February 21, 2024
Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic ModelAnas Saadeddin, Vivek Purohit, Yeamin Huh, et al.
British Journal of Clinical Pharmacology|May 7, 2025
Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450Vivek S Purohit, Yeamin Huh, Martin E Dowty, et al.
The AAPS Journal|March 28, 2023
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsVivek Purohit, Yeamin Huh, Jessica Wojciechowski, et al.
Pediatric Dermatology|February 10, 2025
A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia AreataMercedes E Gonzalez, John Browning, Stacy Smith, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 13, 2010
Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochlorideYeamin Huh, Hyun-Jong Cho, In-Soo Yoon, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 30, 2024
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Sakambari Tripathy, et al.
Pageof 3